MARKET

ALDX

ALDX

Aldeyra
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.69
-0.07
-1.04%
After Hours: 6.70 +0.01 +0.15% 19:30 11/23 EST
OPEN
6.80
PREV CLOSE
6.76
HIGH
6.90
LOW
6.68
VOLUME
268.82K
TURNOVER
--
52 WEEK HIGH
8.70
52 WEEK LOW
1.480
MARKET CAP
259.71M
P/E (TTM)
-5.1537
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aldeyra Therapeutics EPS beats by $0.04
Aldeyra Therapeutics (ALDX): Q4 GAAP EPS of -$0.23 beats by $0.04.Cash, equivalents, and marketable securities of $86.2M expected to support operations through 2022.Press Release
Seekingalpha · 11/05 12:20
Aldeyra Therapeutics Q3 EPS $(0.23) Beats $(0.27) Estimate
Aldeyra Therapeutics (NASDAQ:ALDX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.27) by 14.81 percent. This is a 66.67 percent increase over losses of $(0.69) per share
Benzinga · 11/05 12:16
Aldeyra Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Aldeyra Therapeutics, Inc.
ACCESSWIRE · 11/05 11:15
Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation
Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst. The Aldeyra Analyst: Kelly Shi initiated coverage of Aldeyra shares with a Buy rating and $24 price target.The Aldeyra Thesis: Aldeyra's lead asset reproxalap has substantial opportunity in ocular inflammatory dry eye disease and allergic conjunctivitis, Shi said in a Friday initiation note. With market dominant brands such as Allergan's Restasis and Novartis AG's (NYSE: NVS) Xiidra having pitfalls such as slow onset of drug action and a suboptimal patient experience, there is an unmet need in moderate-to-severe dry eye patients on chronic therapies, the analyst said.Related Link: The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs Aldeyra's reproxalap has shown a differentiated product profile to date, suggesting commercial competitiveness if approved, she said. Two Phase 3 data releases in the first half of 2021 should serve as major catalysts, Shi said."Other progress from Aldeyra's immune-disease focused pipeline in rare ocular disorders, autoimmune diseases, oncology, and Covid set up a catalyst-rich 12 mos to offer further upside." ALDX Price Action: Aldeyra shares gained 5.86% in Friday's session, closing at $6.68. Related Link: The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Latest Ratings for ALDX DateFirmActionFromTo Oct 2020JefferiesInitiates Coverage OnBuy Oct 2020BTIGInitiates Coverage OnBuy Aug 2020CitigroupMaintainsBuy View More Analyst Ratings for ALDX View the Latest Analyst RatingsSee more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 10/31 02:22
GOOG, UAA, SSL and NWL among premarket gainers
Air Industries Group (AIRI) +53% on Q3 results.Equillium (EQ) +24% after FDA gives green signal to it's late-stage COVID-19 trial.BioLineRx (BLRX) +24% on positive late-stage data on lead candidate.Trevena (TRVN) +20%.Miragen Therapeutics (MGEN) +12%.Aldeyra Therapeutics (ALDX)
Seekingalpha · 10/30 12:18
Aldeyra's reproxalap shows positive effect in mid-stage allergic conjunctivitis study
Aldeyra Therapeutics ([[ALDX]] +5.1%) will be presenting new data from Phase 2 allergen chamber trial of reproxalap ophthalmic solution (0.25% and 0.5%) in allergic conjunctivitis, at the American Academy of Ophthalmology
Seekingalpha · 10/22 17:58
Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will present new data from the Phase 2 allergen chamber clinical trial of reproxalap ophthalmic solution (0.25% and 0.5%) in allergic conjunctivitis. The data will be presented in a poster at the American Academy of Ophthalmology 2020 Virtual Annual Meeting (AAO 2020) from November 11 through November 15, 2020.
Business Wire · 10/22 13:00
ReWalk Robotics, Aldeyra Therapeutics leads healthcare gainers; Biomerica, Adaptimmune Therapeutics among major losers
Gainers: ReWalk Robotics (RWLK) +18%, Aldeyra Therapeutics (ALDX) +19%, ClearPoint Neuro (CLPT) +15%, ProPhase Labs (PRPH) +12%, Orchard Therapeutics (ORTX) +11%.Losers: Biomerica (BMRA) -20%, Adaptimmune Therapeutics (ADAP) -14%, Can-Fite BioPharma (CANF) -14%, FSD Pharma (HUGE) -13%, Alterity Therapeutics (ATHE) -9%.
Seekingalpha · 10/16 15:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALDX. Analyze the recent business situations of Aldeyra through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALDX stock price target is 27.44 with a high estimate of 34.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 140
Institutional Holdings: 25.55M
% Owned: 65.82%
Shares Outstanding: 38.82M
TypeInstitutionsShares
Increased
28
8.38M
New
43
2.57M
Decreased
21
1.96M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Independent Director
Richard Douglas
President/Chief Executive Officer/Director
Todd Brady
Chief Financial Officer
Joshua Reed
Senior Vice President
James Gow
Senior Vice President
Stephen Machatha
Other
David McMullin
Independent Director
Ben Bronstein
Independent Director
Martin Joyce
Independent Director
Nancy Miller-rich
Independent Director
Gary Phillips
Independent Director
Jesse Treu
Independent Director
Neal Walker
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALDX
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.